Xeno-free Stem Cell Differentiation for Insulin Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human pluripotent stem cells into insulin-producing pancreatic β-cells are inefficient, resulting in polyhormonal cells with limited glucose-stimulated insulin secretion and reliance on chemically undefined materials, which are not suitable for clinical applications.
Innovation Solution
A 5-step culture system using specific combinations of differentiation-inducing factors, including NOGGIN and IBMX, to direct human induced pluripotent stem cells (hiPS) into functionally mature insulin-producing cells in a xeno-free culture system, promoting efficient differentiation and glucose-stimulated insulin secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional differentiation methods are used to generate pancreatic β-like cells from human pluripotent stem cells, then insulin-producing cells can be obtained, but the cells are polyhormonal and exhibit limited glucose-stimulated insulin secretion capacity
Solution Approach 1:
The differentiation process is divided into five sequential steps, each targeting a specific stage of pancreatic development: (1) definitive endoderm formation, (2) primitive gut tube formation, (3) pancreatic progenitor formation, (4) endocrine progenitor formation, and (5) mature insulin-producing cell formation. This segmentation allows precise control over cell fate decisions at each stage, enabling generation of functionally mature monohormonal β-cells with high differentiation efficiency
Solution Approach 2:
The invention systematically changes chemical parameters at each differentiation stage by introducing specific signaling molecules (activin A, FGF10, retinoic acid, NOGGIN, exendin-4, IBMX, nicotinamide, forskolin) and their combinations in a stepwise manner. These parameter changes guide cells through defined developmental transitions, achieving both high functional maturity and differentiation efficiency
2Ease of manufacture
If chemically undefined raw materials are used in the generation of β-cells, then differentiation can proceed, but clinical application safety is compromised due to potential xenoantigen contamination
Solution Approach 1:
The invention establishes a xeno-free culture environment by replacing all animal-derived components with chemically defined alternatives. The differentiation medium contains only synthetic or recombinant proteins and chemicals, creating an inert environment free from xenoantigens. This maintains differentiation feasibility while ensuring clinical safety
Solution Approach 2:
The invention uses recombinant proteins and synthetic chemicals that can be produced in large quantities through standardized bioprocessing methods. These defined materials replace expensive and variable animal-derived products, enabling scalable manufacturing while eliminating xenocontamination risks
3Manufacturing precision
If stepwise differentiation protocols are used to generate insulin-expressing cells, then pancreatic lineage differentiation is achieved, but the cells remain polyhormonal with limited functional capacity
Solution Approach 1:
The invention applies preliminary actions by pre-treating cells with specific signaling molecules at each developmental stage before final β-cell differentiation. For example, definitive endoderm formation is established first using activin A and GSK3 inhibitor, creating a primed population that is then guided through subsequent stages. This preliminary conditioning ensures cells are properly committed to each lineage stage, achieving both precise lineage differentiation and functional maturity
Solution Approach 2:
The invention uses intermediary cell states as transition zones between pluripotent stem cells and mature β-cells. Each differentiation step produces an intermediate population (definitive endoderm, primitive gut tube, pancreatic progenitor, endocrine progenitor) that serves as a bridge to the next stage. These intermediary states allow gradual acquisition of β-cell functions, ensuring both lineage accuracy and functional maturity
Data Source
Figure 1~3
Figure 4~5
Figure 6
AI summary
It is an object of the present invention to provide a method for efficiently directing differentiation into insulin-producing cells in a xeno-free culture system. According to the present invention, there is provided a method for directed differentiation into insulin-producing cells, comprising culturing stem cells in the following steps (1) to (5): (1) a step of culturing stem cells in a medium comprising an activator of activin receptor-like kinase-4/-7 and a GSK3 inhibitor and then culturing in a medium comprising an activator of activin receptor-like kinase-4/-7; (2) a step of culturing the cells obtained in step (1) in a medium comprising a hedgehog signaling inhibitor and an FGF; (3) a step of culturing the cells obtained in step (2) in a medium comprising a retinoic acid receptor agonist, a hedgehog signaling inhibitor and a BMP signaling inhibitor; (4) a step of culturing the cells obtained in step (3) in a medium comprising a TGF-β type I activin receptor-like kinase-4/-5/-7 inhibitor and a BMP signaling inhibitor; and (5) a step of culturing the cells obtained in step (4) in a medium comprising a phosphodiesterase inhibitor.